AnaptysBio, Inc. (ANAB) vs Generate Biomedicines, Inc. (GENB)

AnaptysBio, Inc. and Generate Biomedicines, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Generate Biomedicines, Inc. are of similar size ($1.4B and $1.3B). Generate Biomedicines, Inc. has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. AnaptysBio, Inc. has the higher net margin (6.54% vs −1,381.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, AnaptysBio, Inc. leads on 11 and Generate Biomedicines, Inc. on 3.

Valuation

Metric ANAB GENB Biotechnology median
P/E 73.58 n/m 10.01
P/S 5.66 59.96 9.02
P/B 65.39 3.31 2.13
Price to free cash flow 308.76 n/m 24.99
EV/EBITDA 13.90 n/m 0.64
EV/Sales 5.04 41.05 9.01
Earnings yield 1.36% (42.17%) (34.01%)
Free cash flow yield 0.32% (20.00%) (24.62%)

Profitability

Metric ANAB GENB Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin 36.14% (1,382.04%) 0.00%
Net margin 6.54% (1,381.76%) 0.00%
Free cash flow margin 0.00% (1,199.36%) 0.00%
Return on equity (365.73%) 1,091.11% (50.72%)
Return on assets 4.76% (56.30%) (45.56%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANAB GENB Biotechnology median
Revenue growth (TTM) 95.19% — 7.42%
EPS growth (last fiscal year) 91.02% (13.66%) 29.36%
Revenue growth, 5-year CAGR 25.62% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ANAB GENB Biotechnology median
Debt to equity 0.17 0.02 0.00
Current ratio 8.40 5.01 4.72
Net debt to EBITDA (6.84) 0.97 1.01

Dividend

Metric ANAB GENB Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ANAB GENB Biotechnology median
Market cap 1.36b 1.27b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack